Jul. 23 at 8:20 PM
$EW Edwards Lifesciences reports Q2 EPS 78c, consensus 74c
Reports Q2 revenue
$1.74B, consensus
$1.70B. In the second quarter, the company reported TAVR sales of
$1.3 billion, which grew 11.3% compared to the prior year, or 10.5% on a constant currency basis. Globally, procedural growth benefited from sustained clinical momentum and the evidence supporting proactive disease management of severe aortic stenosis (AS). At the same time, treatment decisions continued to be shaped by the long-term differentiation of our SAPIEN platform. Edwards' growth rates were similar in the U.S. and outside of the U.S. Growth benefitted from the exit of a competitor in Q2 2025 and compelling long-term SAPIEN durability data. Average selling prices were stable globally.
"We delivered stronger-than-expected second quarter sales growth of 12.5%. As Edwards continues to invest in new structural heart therapies and expand adoption globally, our results increasingly reflect the strength of our comprehensive portfolio and agile execution, with growth supported by therapies across TAVR, mitral, tricuspid and surgical, as well as meaningful contributions from each of the regions," said Bernard Zovighian, Edwards' CEO. "Today, our company profile has evolved to include multiple strategic platforms across multiple regions that will support durable growth, which gives us confidence in our target of approximately 10% total company sales growth, on average, over the longer term. Our strategic focus coupled with our commitment to early innovation enables us to deliver meaningful impact for patients worldwide."
